Zogenix, Inc.  

(Public, NASDAQ:ZGNX)   Watch this stock  
Find more results for James Garner
2.84
+0.03 (1.07%)
After Hours: 2.84 0.00 (0.00%)
Apr 24, 7:32PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.80 - 3.08
52 week 1.25 - 5.19
Open 3.05
Vol / Avg. 3.26M/3.87M
Mkt cap 396.29M
P/E     -
Div/yield     -
EPS -0.71
Shares 139.54M
Beta 2.12
Inst. own 83%
May 21, 2014
Zogenix, Inc. Annual Shareholder Meeting - 8:30AM EDT - Add to calendar
May 5, 2014
Q1 2014 Zogenix, Inc. Earnings Release (Estimated) Add to calendar
Apr 24, 2014
Zogenix Announces Sale of SUMAVEL(R) DosePro(R) Migraine Therapy to Endo International - Webcast
Mar 5, 2014
Q4 2013 Zogenix, Inc. Earnings Conference Call - Webcast
Mar 5, 2014
Q4 2013 Zogenix, Inc. Earnings Release
Feb 12, 2014
Zogenix, Inc. at Leerink Swann Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -359.00% -244.93%
Operating margin -146.29% -161.13%
EBITD margin - -153.00%
Return on average assets -170.94% -83.71%
Return on average equity -6297.35% -491.54%
Employees 114 -
CDP Score - -

Address

Suite 650, 12400 High Bluff Drive
SAN DIEGO, CA 92130
United States - Map
+1-858-2591165 (Phone)
+1-858-2591166 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Zogenix, Inc. (Zogenix) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy. It completed Phase 3 development of Zohydro in 2011. Its second DosePro investigational product candidate, Relday, is a injectable formulation of risperidone for the treatment of schizophrenia. In April 2014, Endo International PLC acquired worldwide rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix, Inc.

Officers and directors

Cam L. Garner Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Stephen J. Farr Ph.D. President, Director
Age: 54
Bio & Compensation  - Reuters
Roger L. Hawley Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Ann D. Rhoads Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Age: 47
Bio & Compensation  - Reuters
Bradley S. Galer M.D. Executive Vice President and Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
R. Scott Shively Executive Vice President, Chief Commercial Officer
Age: 56
Bio & Compensation  - Reuters
Cynthia Y. Robinson Ph.D. Chief Development Officer
Age: 54
Bio & Compensation  - Reuters
James B. Breitmeyer M.D., Ph.D. Director
Age: 60
Bio & Compensation  - Reuters
James C. Blair Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 48
Bio & Compensation  - Reuters